Generation of iPSCs from genetically corrected Brca2 hypomorphic cells: Implications in cell reprogramming and stem cell therapy

Stem Cells

Volumn 32, Issue 2, 2014, Pages 436-446

  Navarro, S ^a,b   Moleiro, V ^a,b   Molina Estevez, F J ^a,b   Lozano, M L ^a,b   Chinchon, R ^a,b   Almarza, E ^a,b   Quintana Bustamante, O ^a,b   Mostoslavsky, G ^c   Maetzig, T ^d   Galla, M ^d   Heinz, N ^d   Schiedlmeier, B ^d   Torres, Y ^e   Modlich, U ^d   Samper, E ^e   Rio P ^a,b   Segovia, J C ^a,b   Raya, A ^f,g   Guenechea G ^a,b   Izpisua Belmonte, J C ^g,h,i   Bueren, J A ^a   more..

^a CIEMAT   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e NIMGenetics   (Spain)

^f INSTITUTE FOR BIOENGINEERING OF CATALONIA IBEC   (Spain)

^g BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^h CENTER OF REGENERATIVE MEDICINE IN BARCELONA   (Spain)

ⁱ SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Bone marrow aplasia; Cellular therapy; Fanconi anemia; Gene therapy; Hematopoietic stem cells; Induced pluripotent stem cells

Indexed keywords

BONE MARROW APLASIA; CELLULAR THERAPY; FANCONI ANEMIA; GENE THERAPY; HEMATOPOIETIC STEM CELLS; INDUCED PLURIPOTENT STEM CELLS;

ANIMALS; BRCA2 PROTEIN; CELL DIFFERENTIATION; CELLS, CULTURED; DNA DAMAGE; FANCONI ANEMIA; FIBROBLASTS; GENETIC THERAPY; HEMATOPOIETIC STEM CELLS; INDUCED PLURIPOTENT STEM CELLS; MICE; NUCLEAR REPROGRAMMING;

EID: 84894600272     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1586     Document Type: Article

References (52)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126: 663-676.
2. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131: 861-872.
3. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-1920.
4. Stadtfeld M, Nagaya M, Utikal J et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322: 945-949.
5. Tiscornia G, Vivas EL, Belmonte JC. Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nat Med 2011;17: 1570-1576.
6. Daley GQ. Towards the generation of patient-specific pluripotent stem cells for combined gene and cell therapy of hematologic disorders. Hematology Am Soc Hematol 2007: 17-22.
7. Marion RM, Strati K, Li H et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009;460: 1149-1153.
8. Li H, Collado M, Villasante A et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009;460: 1136-1139.
9. Utikal J, Polo JM, Stadtfeld M et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009;460: 1145-1148.
10. Hong H, Takahashi K, Ichisaka T et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009;460: 1132-1135.
11. Banito A, Rashid ST, Acosta JC et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 2009;23: 2134-2139.
12. Batista LF, Pech MF, Zhong FL et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 2011;474: 399-402.
13. Fong YW, Inouye C, Yamaguchi T et al. A DNA repair complex functions as an Oct4/Sox2 coactivator in embryonic stem cells. Cell 2011;147: 120-131.
14. Raya A, Rodriguez-Piza I, Guenechea G et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009;460: 53-59.
15. Müller LU, Milsom MD, Harris CE et al. Overcoming reprogramming resistance of Fanconi anemia cells. Blood 2012;119: 5449-5457.
16. Yung SK, Tilgner K, Ledran MH et al. Human pluripotent stem cell models of Fanconi anaemia deficiency reveal an important role for Fanconi anaemia proteins in cellular reprogramming and survival of haematopoietic progenitors. Stem Cells 2013;31: 1022-1029.
17. Gonzalez F, Georgieva D, Vanoli F et al. Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. Cell Rep 2013;3: 651-660.
18. Tilgner K, Neganova I, Moreno-Gimeno I et al. A human iPSC model of Ligase IV deficiency reveals an important role for NHEJmediated-DSB repair in the survival and genomic stability of induced pluripotent stem cells and emerging haematopoietic progenitors. Cell Death Differ 2013;20: 1089-1100.
19. Molina-Estevez FJ, Lozano ML, Navarro S et al. Impaired cell reprogramming in nonhomologous end joining deficient cells. Stem Cells 2013;31: 1726-1730.
20. Hanna J, Wernig M, Markoulaki S et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318: 1920-1923.
21. McAllister KA, Bennett LM, Houle CD et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res 2002; 62: 990-994.
22. Navarro S, Meza NW, Quintana-Bustamante O et al. Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1. Mol Ther 2006;14: 525-535.
23. Cheng NC, van de Vrugt HJ, van der Valk MA et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet 2000;9: 1805-1811.
24. Raya A, Rodriguez-Piza I, Navarro S et al. A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. Nat Protoc 2010;5: 647-660.
25. Rio P, Meza NW, Gonzalez-Murillo A et al. In vivo proliferation advantage of genetically corrected hematopoietic stem cells in a mouse model of Fanconi anemia FA-D1. Blood 2008;112: 4853-4861.
26. Sommer CA, Stadtfeld M, Murphy GJ et al. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009;27: 543-549.
27. Charrier S, Ferrand M, Zerbato M et al. Quantification of lentiviral vector copy numbers in individual hematopoietic colonyforming cells shows vector dose-dependent effects on the frequency and level of transduction. Gene Ther 2011;18: 479-487.
28. Chan KM, Bonde S, Klump H et al. Hematopoiesis and immunity of HOXB4-transduced embryonic stem cell-derived hematopoietic progenitor cells. Blood 2008; 111: 2953-2961.
29. Barrett MT, Scheffer A, Ben-Dor A et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci USA 2004;101: 17765-17770.
30. Godthelp BC, Wiegant WW, Waisfisz Q et al. Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2. Mutat Res 2006;594: 39-48.
31. Kitajima K, Minehata K, Sakimura K et al. In vitro generation of HSC-like cells from murine ESCs/iPSCs by enforced expression of LIM-homeobox transcription factor Lhx2. Blood 2011;117: 3748-3758.
32. Lesinski DA, Heinz N, Pilat-Carotta S et al. Serum-and stromal cell-free hypoxic generation of embryonic stem cell-derived hematopoietic cells in vitro, capable of multilineage repopulation of immunocompetent mice. Stem Cells Transl Med 2012;1: 581-591.
33. Jacome A, Navarro S, Casado JA et al. A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in Fanconi anemia patients. Hum Gene Ther 2006;17: 245-250.
34. Tulpule A, Lensch MW, Miller JD et al. Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood 2010;115: 3453-3462.
35. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448: 313-317.
36. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000;24: 372-376.
37. Mayshar Y, Ben-David U, Lavon N et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010;7: 521-531.
38. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011;471: 58-62.
39. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011;471: 63-67.
40. Lister R, Pelizzola M, Kida YS et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011;471: 68-73.
41. Laurent LC, Ulitsky I, Slavin I et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011;8: 106-118.
42. Blasco MA, Serrano M, Fernandez-Capetillo O. Genomic instability in iPS: Time for a break. EMBO J 2011;30: 991-993.
43. Pasi CE, Dereli-Oz A, Negrini S et al. Genomic instability in induced stem cells. Cell Death Differ 2011;18: 745-753.
44. Young MA, Larson DE, Sun CW et al. Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells. Cell Stem Cell 2012;10: 570-582.
45. Pilat S, Carotta S, Schiedlmeier B et al. HOXB4 enforces equivalent fates of ES-cellderived and adult hematopoietic cells. Proc Natl Acad Sci USA 2005;102: 12101-12106.
46. Bonde S, Dowden AM, Chan KM et al. HOXB4 but not BMP4 confers self-renewal properties to ES-derived hematopoietic progenitor cells. Transplantation 2008;86: 1803-1809.
47. Mukherjee S, Santilli G, Blundell MP et al. Generation of functional neutrophils from a mouse model of X-linked chronic granulomatous disorder using induced pluripotent stem cells. PLoS One 2011;6: e17565.
48. Schenke-Layland K, Rhodes KE, Angelis E et al. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells 2008;26: 1537-1546.
49. Woods NB, Parker AS, Moraghebi R et al. Brief report: Efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines. Stem Cells 2011;29: 1158-1164.
50. Ramos-Mejia V, Montes R, Bueno C et al. Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD341 progenitors. PLoS One 2012;7: e35824.
51. Jiang Y, Cowley SA, Siler U et al. Derivation and functional analysis of patientspecific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. Stem Cells 2012;30: 599-611.
52. Xu Y, Liu L, Zhang L et al. Efficient commitment to functional CD341 progenitor cells from human bone marrow mesenchymal stem-cell-derived induced pluripotent stem cells. PLoS One 2012;7: e34321.